Company Filing History:
Years Active: 2009-2010
Title: Innovations by Jennifer Rebecca Lo in the Field of Central Nervous System Disorders
Introduction
Jennifer Rebecca Lo, an accomplished inventor based in Plainsboro, NJ, has made significant contributions to the field of pharmacology with three innovative patents. Her work primarily focuses on developing compounds that target the 5-hydroxytryptamine-6 (5-HT6) receptor, which is crucial in treating various central nervous system disorders.
Latest Patents
Among her latest patents, Jennifer has developed two noteworthy compounds:
1. **Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands** - This invention provides a compound of formula I designed for therapeutic use in treating central nervous system disorders associated with the 5-HT6 receptor.
2. **Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands** - Similar to her first patent, this invention also offers a compound of formula I that holds promise in the treatment of central nervous system disorders linked to the 5-HT6 receptor.
Career Highlights
Jennifer works at Wyeth, a leading pharmaceutical company renowned for its commitment to advancing healthcare solutions. Her innovative spirit and dedication to research have contributed to the company's mission of discovering and delivering innovative therapies. With a robust portfolio of patents, Jennifer stands out as a pivotal figure within her organization.
Collaborations
Throughout her career, Jennifer has had the opportunity to collaborate with several talented individuals, including Hassan Mahmoud Elokdah and Kevin G Liu. These partnerships have enriched her research and development efforts, facilitating a collaborative environment that fosters innovation in the pharmaceutical industry.
Conclusion
Jennifer Rebecca Lo's contributions to the realm of inventions related to central nervous system disorders exemplify her dedication to scientific advancement. With her innovative patents and collaborations within Wyeth, she continues to push the boundaries of medication development, providing hope for those affected by these challenging conditions.